Identification and characterization of degradation products of indacaterol using liquid chromatography/mass spectrometry

Abstract

Indacaterol (IND), 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one, is an active pharmaceutical ingredient (API) which is used to treat chronic obstructive pulmonary disease (COPD). We followed the International Council for Harmonization (ICH) guide lines to study the degradation behavior of IND under various stress conditions. Stressed degradation of the drug was performed under hydrolytic (alkaline, acidic and neutral), photolytic, oxidative and thermal conditions. Identification and characterization of IND and its forced degradation products (DPs) were demonstrated by using LC-HRMS and MS/MS method. A total of three DPs (DP1-DP3) were identified and characterized. The IND was found to be stable under photolytic, oxidative and thermal conditions, whereas it produced three DPs in acidic, basic and neutral hydrolytic stress conditions.

Keywords

Indacaterol stress degradation UPLC/DAD/ESI-QTOF accurate mass measurements

Get full access to this article

View all access options for this article.

References

Vestbo

Hurd

Agusti

, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.

Roversi

Corbetta

Clini

GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Res Pract 2017; 3: 1–6.

Afonso

Verhamme

Sturkenboom

, et al. COPD in the general population: prevalence, incidence and survival. Respir Med 2011; 105: 1872–1884.

Zayed

Belal

Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method. Chem Cent J 2017; 11: 36–01.

Beeh

Beier

Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Adv Ther 2009; 26: 691–699.

Dahl

Jadayel

Alagappan

, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013; 8: 501–508.

Tashkin

DP.

Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2010; 11: 2077–2085.

International Conference on Harmonization. Q1A(R2), Stability testing of new drug substances and products. Geneva: International Conference on Harmonization, 2003.

Baira

Kalariya

Nimbalkar

, et al. Characterization of forced degradation products of canagliflozine by liquid chromatography/quadrupole time-of-flight tandem mass spectrometry and in silico toxicity predictions. Rapid Commun Mass Spectrom 2018; 32: 212–220.

10.

Blessy

Patel

Prajapati

, et al. Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 2014; 4: 159–165.

11.

Jain

Basniwal

PK.

Forced degradation and impurity profiling: recent trends in analytical perspectives. J Pharm Biomed Anal 2013; 86: 11–35.

12.

Pandeti

Narender

Prabhakar

, et al. Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry. Rapid Commun Mass Spectrom 2017; 31: 572–582.

13.

Pandeti

Rout

Tadigoppula

, et al. Identification of stress degradation products of iloperidone using liquid chromatography coupled with an orbitrap mass spectrometer. Rapid Commun Mass Spectrom 2017; 31: 1324–1332.

14.

Yerra

Pallerla

Pandeti

, et al. Characterization of degradation products of Macitentan under various stress conditions using liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2018; 32: 1075–1084.

15.

Ghany

MFA

Hussein

Magdy

, et al. Simultaneous spectrophotometric determination of indacaterol and glycopyrronium in a newly approved pharmaceutical formulation using different signal processing techniques of ratio spectra. Spectrochim Acta A 2016; 157: 251–257.

16.

Salem

El-Sherbiny

El-Wasseef

, et al. Spectroscopic study on indacaterol maleate: analytical applications for quality control of capsules. Int J Pharma Sci Res 2015; 6: 592–605.

17.

Salem

El-Sherbiny

El-Wasseef

, et al. HPLC determination of indacaterol maleate in pharmaceutical preparations adopting ultraviolet and fluorescence detection. Int J Pharmaceut Sci Res 2015; 6: 1324–1332.

18.

ICH Guideline. Q1B photo stability testing on new drug substances and products, international conference on harmonization. Geneva: International Federation of Pharmaceutical Manufacturers & Associations, 2000.

19.

Mohammadi

Esmaeili

Dinarvand

, et al. Development and validation of a stability-indicating method for the quantitation of paclitaxel in pharmaceutical dosage forms. J Chromatogr Sci 2009; 47: 599–604.

20.

Bakshi

Singh

Development of validated stability-indicating assay methods—critical review. J Pharmaceut Biomed 2002; 28: 1011–1040.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.37 MB